News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Molecular Partners AG Reports Positive Results from Its First Clinical Studies



4/28/2011 10:29:06 AM

ZURICH-SCHLIEREN, Switzerland--(BUSINESS WIRE)--Molecular Partners AG, a leader in the development of next generation therapeutics, announced today that it has completed two phase I/IIa clinical trials with MP0112, its lead molecule targeting VEGF-A. The DARPin molecule was shown to be safe and well tolerated in two separate Phase I/IIa trials in wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES